(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Pick Your Favored kind of books- Excelling at Cash The board: A Manual for Monetary Essentials
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Vote in favor of your Number one Kind of Gems
- Believe Should Unwind? Look at These Scaled down Games
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
